{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/622b8f5080a3a00013890f23/6696eb02b71d5799b567b19a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Wednesday, July 17, 2024","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/622b8f5080a3a00013890f23/1721166548213-84e3a79674413b723f68adcfef2a8395.jpeg?height=200","description":"<p>The House Appropriations Committee is requesting that the FDA holds off on regulating laboratory developed tests.&nbsp;A recent report finds that private equity-backed providers account for less than 4 percent of the U.S. provider market by revenue.&nbsp;And a new study links semaglutide to lower risk for both dementia and nicotine use. That’s coming up on today’s episode of Gist Healthcare Daily.&nbsp;</p>","author_name":"Gist Healthcare Daily"}